Legal & General Group Plc Buys 2,363 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Legal & General Group Plc increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 23.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,319 shares of the company’s stock after purchasing an additional 2,363 shares during the quarter. Legal & General Group Plc’s holdings in Dianthus Therapeutics were worth $269,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jane Street Group LLC bought a new stake in Dianthus Therapeutics during the 3rd quarter valued at $556,000. Barclays PLC raised its holdings in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after acquiring an additional 33,185 shares during the period. Alliancebernstein L.P. raised its holdings in Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after acquiring an additional 136,633 shares during the period. FMR LLC raised its holdings in Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after acquiring an additional 36,133 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares during the period. Institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

DNTH has been the subject of a number of recent analyst reports. Guggenheim restated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Trading Up 0.5 %

Shares of NASDAQ DNTH opened at $21.85 on Thursday. The stock has a market cap of $701.95 million, a price-to-earnings ratio of -8.74 and a beta of 1.62. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27. The stock’s 50-day moving average is $19.86 and its 200 day moving average is $22.78.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.